Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer

AJ Young, AR Pantel, V Viswanath… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The poly-(adenosine diphosphate-ribose) polymerase (PARP) family of proteins participates
in numerous functions, most notably the DNA damage response. Cancer vulnerability to …

The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1

HS Lee, SW Schwarz, EK Schubert, DL Chen… - Radiology: Imaging …, 2022 - pubs.rsna.org
Fluorine 18 (18F) fluorthanatrace (18F-FTT) is a PET radiotracer for imaging poly
(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an important target for a class of …

PET of poly (ADP-ribose) polymerase activity in cancer: preclinical assessment and first in-human studies

LS Michel, S Dyroff, FJ Brooks, KJ Spayd, S Lim… - Radiology, 2017 - pubs.rsna.org
Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 (18F)
fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate–ribose) polymerase …

PET imaging of PARP expression using 18F-olaparib

TC Wilson, MA Xavier, J Knight… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Poly (ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer
drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a …

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

AR Pantel, SB Gitto, M Makvandi, H Kim… - Clinical Cancer …, 2023 - AACR
Purpose: PARP inhibitors have become the standard-of-care treatment for homologous
recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not …

[HTML][HTML] [18F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging

F Guibbal, SL Hopkins, A Pacelli, PG Isenegger… - Molecular Imaging and …, 2020 - Springer
Background Poly (ADP-ribose) polymerase (PARP) inhibitors are extensively studied and
used as anti-cancer drugs, as single agents or in combination with other therapies. Most …

Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer

SLV Hoffman, JC Mixdorf, O Kwon, TR Johnson… - Nuclear Medicine and …, 2023 - Elsevier
Advanced ovarian cancer currently has few therapeutic options. Poly (ADP-ribose)
polymerase (PARP) inhibitors bind to nuclear PARP and trap the protein-inhibitor complex to …

[18F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity

AJ Shuhendler, L Cui, Z Chen, B Shen… - Bioconjugate …, 2019 - ACS Publications
Poly (ADP ribose) polymerase (PARP) enzymes generate poly (ADP ribose) post-
translational modifications on target proteins for an array of functions centering on DNA and …

[HTML][HTML] A PET imaging agent for evaluating PARP-1 expression in ovarian cancer

M Makvandi, A Pantel, L Schwartz… - The Journal of …, 2018 - Am Soc Clin Investig
BACKGROUND. Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in a broad
population of patients with ovarian cancer; however, resistance caused by low enzyme …

Molecular imaging: PARP-1 and beyond

LN Puentes, M Makvandi, RH Mach - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
The genetic code to life is balanced on a string of DNA that is under constant metabolic and
physical stress from environmental forces. Nearly all diseases have a genetic component …